LYTIX Stock Overview
A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Lytix Biopharma AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 5.16 |
| 52 Week High | NOK 15.00 |
| 52 Week Low | NOK 5.04 |
| Beta | -0.62 |
| 1 Month Change | -11.03% |
| 3 Month Change | -19.38% |
| 1 Year Change | -24.12% |
| 3 Year Change | -48.91% |
| 5 Year Change | n/a |
| Change since IPO | -72.26% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Aug 31
We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Mar 02We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Oct 04We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Jun 21Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth
Jan 11We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jul 16We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jan 25We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Sep 14Shareholder Returns
| LYTIX | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -9.8% | -0.5% | -2.0% |
| 1Y | -24.1% | -57.3% | 8.8% |
Return vs Industry: LYTIX exceeded the Norwegian Biotechs industry which returned -57.3% over the past year.
Return vs Market: LYTIX underperformed the Norwegian Market which returned 8.8% over the past year.
Price Volatility
| LYTIX volatility | |
|---|---|
| LYTIX Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 14.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 13.0% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: LYTIX's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: LYTIX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oystein Rekdal | www.lytixbiopharma.com |
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases.
Lytix Biopharma AS Fundamentals Summary
| LYTIX fundamental statistics | |
|---|---|
| Market cap | NOK 352.23m |
| Earnings (TTM) | -NOK 94.26m |
| Revenue (TTM) | NOK 11.13m |
31.6x
P/S Ratio-3.7x
P/E RatioIs LYTIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYTIX income statement (TTM) | |
|---|---|
| Revenue | NOK 11.13m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 11.13m |
| Other Expenses | NOK 105.40m |
| Earnings | -NOK 94.26m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 10, 2025
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 100.00% |
| Net Profit Margin | -846.64% |
| Debt/Equity Ratio | 0% |
How did LYTIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 02:41 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lytix Biopharma AS is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |